Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer, ...
Jan 10, 2013
0
0
(Medical Xpress)—An international team of researchers has developed a new anti-cancer drug that holds promise as a therapy that fights cancer while causing fewer side effects than current medicines. The work done by the ...
(Medical Xpress)—As anyone familiar with the X-Men knows, mutants can be either very good or very bad—or somewhere in between. The same appears true within cancer cells, which may harbor hundreds of mutations that set ...
Dec 27, 2012
0
0
Researchers at McGill University have discovered that a key regulator of energy metabolism in cancer cells known as the AMP-activated protein kinase (AMPK) may play a crucial role in restricting cancer cell growth. AMPK acts ...
Dec 27, 2012
0
0
A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's ...
Dec 26, 2012
0
0
Relatives of family members diagnosed with cancer are still at risk of the disease even if the diagnosis came at an older age, suggests a paper published on BMJ website today.
Dec 20, 2012
0
0
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
Dec 14, 2012
0
0
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers ...
Dec 14, 2012
0
0
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American ...
Dec 10, 2012
0
0
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Dec 10, 2012
0
0
